Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: The oncologist, 2021, online version before inclusion in an issue, doi:10.1002/onco.13955
- Event
-
Veröffentlichung
- (where)
-
Frankfurt am Main
- (who)
-
Universitätsbibliothek Johann Christian Senckenberg
- (when)
-
2021
- Creator
- URN
-
urn:nbn:de:hebis:30:3-644133
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:33 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Trojan, Jörg
- Stintzing, Sebastian
- Haase, Oliver
- Koch, Christine
- Ziegler, Paul
- Demes, Melanie Christin
- Jelas, Ivan
- Universitätsbibliothek Johann Christian Senckenberg
Time of origin
- 2021
Other Objects (12)
Complete pathological response after neoadjuvant short-course immunotherapy with Ipilimumab and Nivolumab in locally advanced MSI-H/dMMR rectal cancer
Nivolumab (Kolorektalkarzinom mit MSI-H oder dMMR) : Nutzenbewertung gemäß § 35a SGB V
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial
Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial
Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom
Therapie des rezidivierenden/fortgeschrittenen dMMR/MSI-H Endometriumkarzinoms : Dostarlimab
Dostarlimab beim rezidivierenden oder fortgeschrittenen dMMR/MSI-H-Endometriumkarzinom
Concordance between immunohistochemistry and MSI analysis for detection of MMR/MSI status in colorectal cancer patients
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms
Severe Gastritis after Administration of Nivolumab and Ipilimumab
PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma
Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease
Complete pathological response after neoadjuvant short-course immunotherapy with Ipilimumab and Nivolumab in locally advanced MSI-H/dMMR rectal cancer
Nivolumab (Kolorektalkarzinom mit MSI-H oder dMMR) : Nutzenbewertung gemäß § 35a SGB V
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial
Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial
Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom
Therapie des rezidivierenden/fortgeschrittenen dMMR/MSI-H Endometriumkarzinoms : Dostarlimab
Dostarlimab beim rezidivierenden oder fortgeschrittenen dMMR/MSI-H-Endometriumkarzinom
Concordance between immunohistochemistry and MSI analysis for detection of MMR/MSI status in colorectal cancer patients
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms
Severe Gastritis after Administration of Nivolumab and Ipilimumab
PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma
Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease
Complete pathological response after neoadjuvant short-course immunotherapy with Ipilimumab and Nivolumab in locally advanced MSI-H/dMMR rectal cancer
Nivolumab (Kolorektalkarzinom mit MSI-H oder dMMR) : Nutzenbewertung gemäß § 35a SGB V
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial
Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial
Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom
Therapie des rezidivierenden/fortgeschrittenen dMMR/MSI-H Endometriumkarzinoms : Dostarlimab
Dostarlimab beim rezidivierenden oder fortgeschrittenen dMMR/MSI-H-Endometriumkarzinom
Concordance between immunohistochemistry and MSI analysis for detection of MMR/MSI status in colorectal cancer patients
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms
Severe Gastritis after Administration of Nivolumab and Ipilimumab
PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma